The clinical expression of T2DM usually follows a decrease in the responsiveness (increase in the resistance) to insulin (especially in skeletal muscle, liver, and adipose tissue) and a decrease in insulin secretory response to hyperglycemia by pancreatic β cells. The gene discussed is INS; the disease is type 2 diabetes mellitus.